Funder
Medical University of Graz
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Reproductive Medicine,Endocrinology, Diabetes and Metabolism
Reference10 articles.
1. Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483
2. Perren T, Swart AM, Pfsterer J, Ledermann J, Pujade-Lauraine E, Kristensen G et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496
3. Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, DuBois A, Petru E et al (2013) S3-guideline on diagnostics, therapy and follow-up of malignant ovarian tumours. Geburtshilfe Frauenheilkd 73:874–889
4. Pignata S, Scambia G, Savarese A et al (2010) Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin in patients with advanced ovarian cancer: final analysis of the MITO‑2 randomized multicenter trial. J Clin Oncol 28(Suppl):952s (Abstract No. LBA5033)
5. Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke G, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe E, Bloomfield R, DiSilvestro P (2018) Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 379(26):2495–2505. https://doi.org/10.1056/NEJMoa1810858